Tofacitinib in ulcerative colitis

Keyphrases

• Acceptable Safety 33%
• Autoimmune Pathology 33%
• Cytokine Receptor 33%
• Cytokine Receptor Signaling 33%
• Eukaryotic Cells 33%
• IL-1 Family Cytokines 33%
• Immune Response 33%
• Inflammatory Response 33%
• Janus Kinase 66%
• Janus Kinase Inhibitors 66%
• Mode of Use 33%
• Protein Kinase 33%
• Rheumatoid Arthritis 33%
• Safety Profile 33%
• Safety Self-efficacy 33%
• Signal Transduction 33%
• Th2 Cytokines 33%
• Tofacitinib 100%
• Tyrosine Kinase 33%
• Ulcerative Colitis 100%
• Ulcerative Colitis Therapy 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Autoimmune Disease 25%
• Cytokine 50%
• Cytokine Receptor 50%
• Inflammation 25%
• Inflammatory Arthritis 25%
• Janus Kinase 1 50%
• Janus Kinase Inhibitor 50%
• Protein Kinases 25%
• Protein Tyrosine Kinase 25%
• Rheumatoid Arthritis 25%
• Tofacitinib 100%
• Ulcerative Colitis 100%